Works matching IS 03682811 AND DT 2023 AND VI 53 AND IP 3

Results: 14
    1
    2

    Patient-reported outcome and quality of life research policy: Japan Clinical Oncology Group (JCOG) policy.

    Published in:
    Japanese Journal of Clinical Oncology, 2023, v. 53, n. 3, p. 195, doi. 10.1093/jjco/hyad007
    By:
    • Ishiki, Hiroto;
    • Kikawa, Yuichiro;
    • Terada, Mitsumi;
    • Mizusawa, Junki;
    • Honda, Michitaka;
    • Iwatani, Tsuguo;
    • Mizutani, Tomonori;
    • Mori, Keita;
    • Nakamura, Naoki;
    • Miyaji, Tempei;
    • Yamaguchi, Takuhiro;
    • Ando, Masahiko;
    • Nakamura, Kenichi;
    • Fukuda, Haruhiko;
    • Kiyota, Naomi;
    • Group, PRO/QOL research Committee of Japan Clinical Oncology
    Publication type:
    Article
    3
    4
    5
    6
    7

    Renal function outcome after selective bladder-preserving tetramodality therapy consisting of maximal transurethral resection, induction chemoradiotherapy and consolidative partial cystectomy in comparison with radical cystectomy for patients with muscle-invasive bladder cancer: a two-centre retrospective study

    Published in:
    Japanese Journal of Clinical Oncology, 2023, v. 53, n. 3, p. 263, doi. 10.1093/jjco/hyac190
    By:
    • Fujiwara, Motohiro;
    • Yokoyama, Minato;
    • Toide, Masahiro;
    • Fujiwara, Ryo;
    • Tanaka, Hajime;
    • Oguchi, Tomohiko;
    • Komai, Yoshinobu;
    • Yoshida, Soichiro;
    • Matsuoka, Yoh;
    • Numao, Noboru;
    • Yamamoto, Shinya;
    • Fukui, Iwao;
    • Yonese, Junji;
    • Fujii, Yasuhisa
    Publication type:
    Article
    8
    9

    Pembrolizumab or pembrolizumab plus chemotherapy versus standard of care chemotherapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma: Asian subgroup analysis of KEYNOTE-062.

    Published in:
    Japanese Journal of Clinical Oncology, 2023, v. 53, n. 3, p. 221, doi. 10.1093/jjco/hyac188
    By:
    • Satake, Hironaga;
    • Lee, Keun-Wook;
    • Chung, Hyun Cheol;
    • Lee, Jeeyun;
    • Yamaguchi, Kensei;
    • Chen, Jen-Shi;
    • Yoshikawa, Takaki;
    • Amagai, Kenji;
    • Yeh, Kun-Huei;
    • Goto, Masahiro;
    • Chao, Yee;
    • Lam, Ka-On;
    • Han, Shi Rong;
    • Shiratori, Shinichi;
    • Shah, Sukrut;
    • Shitara, Kohei
    Publication type:
    Article
    10

    Switch-maintenance avelumab immunotherapy following first-line chemotherapy for patients with advanced, unresectable or metastatic urothelial carcinoma: the first Japanese real-world evidence from a multicenter study.

    Published in:
    Japanese Journal of Clinical Oncology, 2023, v. 53, n. 3, p. 253, doi. 10.1093/jjco/hyac186
    By:
    • Miyake, Makito;
    • Shimizu, Takuto;
    • Oda, Yuki;
    • Tachibana, Akira;
    • Ohmori, Chihiro;
    • Itami, Yoshitaka;
    • Kiba, Keisuke;
    • Tomioka, Atsushi;
    • Yamamoto, Hiroaki;
    • Ohnishi, Kenta;
    • Nishimura, Nobutaka;
    • Hori, Shunta;
    • Morizawa, Yosuke;
    • Gotoh, Daisuke;
    • Nakai, Yasushi;
    • Torimoto, Kazumasa;
    • Fujii, Tomomi;
    • Tanaka, Nobumichi;
    • Fujimoto, Kiyohide
    Publication type:
    Article
    11
    12
    13
    14

    Retrospective study on the effectiveness of medroxyprogesterone acetate in the treatment of ER-positive/HER2-negative post-menopausal advanced breast cancer: an additional analysis of the JBCRG-C06 Safari study.

    Published in:
    Japanese Journal of Clinical Oncology, 2023, v. 53, n. 3, p. 203, doi. 10.1093/jjco/hyac184
    By:
    • Kawaguchi, Hidetoshi;
    • Yamamoto, Yutaka;
    • Saji, Shigehira;
    • Masuda, Norikazu;
    • Nakayama, Takahiro;
    • Aogi, Kenjiro;
    • Anan, Keisei;
    • Ohtani, Shoichiro;
    • Sato, Nobuaki;
    • Takano, Toshimi;
    • Tokunaga, Eriko;
    • Nakamura, Seigo;
    • Hasegawa, Yoshie;
    • Hattori, Masaya;
    • Fujisawa, Tomomi;
    • Morita, Satoshi;
    • Yamaguchi, Miki;
    • Yamashita, Toshinari;
    • Yotsumoto, Daisuke;
    • Toi, Masakazu
    Publication type:
    Article